News | July 19, 2021
Lonza extends collaboration with Biopharma company
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
The facility is expected to be completed in 2024
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Essential medicines were made available to more than 150 countries around the world during the pandemic
India produces 60% of the world’s vaccine
Subscribe To Our Newsletter & Stay Updated
